Fatty Acid Analogs Modulating PPAR Agonist Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for metabolic syndrome often have undesirable side effects and are limited in effectively addressing early stages and prevention, particularly for individuals who cannot comply with dietary and exercise regimens.
Innovation Solution
Compositions comprising fatty acid compounds, including saturated fatty acid analogs with specific substituents, are administered to modulate markers associated with metabolic syndrome and related conditions, such as cardiovascular disease and diabetes, by activating PPAR agonists.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (metformin, insulin, statins, fibrates, niacin) are administered to treat metabolic syndrome, then conditions such as diabetes and cardiovascular disease are addressed, but undesirable side effects occur
Solution Approach 1:
The patent modifies the chemical structure of natural fatty acids by introducing specific substituents (methyl, ethyl, hydroxyl groups) at defined positions along the carbon chain. These structural parameter changes create analogs that maintain PPAR agonist activity while reducing harmful side effects associated with conventional medications like metformin and statins
Solution Approach 2:
The invention creates composite molecular structures by combining the core fatty acid backbone with specific functional substituents. Examples include 3-hydroxy-2-methyl-pentadecanoic acid and 3-hydroxy-2,2-dimethyl-pentadecanoic acid, where the combination of hydroxyl and methyl/ethyl groups produces synergistic therapeutic effects with improved safety profiles
2Ease of operation
If dietary and exercise regimens are recommended for early stage metabolic syndrome, then treatment is provided, but subjects unable to comply or unresponsive to these regimens cannot be effectively treated
Solution Approach 1:
The fatty acid analogs act as self-administered therapeutic agents that directly modulate PPAR receptors to improve metabolic parameters. Unlike dietary regimens requiring patient compliance, these compounds are administered as medications that automatically exert their therapeutic effect through biochemical mechanisms, making treatment effective regardless of patient behavior or lifestyle changes
3Reliability
If natural fatty acids are used for treatment, then PPAR agonist activity is provided, but effectiveness is limited compared to modified analogs
Solution Approach 1:
The patent introduces specific local modifications at defined positions along the fatty acid carbon chain. For example, placing a methyl group at position 2 and a hydroxyl group at position 3, or adding ethyl groups at specific locations, creates localized structural features that enhance PPAR binding affinity and agonist activity, making the analogs more effective than unmodified natural fatty acids
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The fatty acid compositions effectively treat and prevent metabolic syndrome and associated conditions by improving PPAR agonist activity, providing a more effective alternative to natural fatty acids with reduced side effects.
Implementation Method 1
by activating PPAR agonists
Data Source
AI summary
Compositions comprising fatty acid analogs are provided for treating metabolic syndrome, anemia, cancer, cardiovascular disease, diabetes, dyslipidemia, hypertension, inflammation, insulin resistance, prediabetes, fatty liver disease, steatohepatitis, iron overload, neurodegenerative diseases, including Alzheimer's disease and other forms of dementia, and other related conditions. Methods for the diagnosis and monitoring of metabolic syndrome and other conditions are also provided.